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Predicting clinical outcomes in patients with chronic hepatitis C is challenging. We used
the hepatitis C long-term treatment against cirrhosis (HALT-C) trial database to develop
two models, using baseline values of routinely available laboratory tests together with
changes in these values during follow-up to predict clinical decompensation and liver-
related death/liver transplant in patients with advanced hepatitis C. Patients randomized
to no treatment and who had 2-year follow-up without a clinical outcome were included
in the analysis. Four variables (platelet count, aspartate aminotransferase [AST]/alanine
aminotransferase [ALT] ratio, total bilirubin, and albumin) with three categories of change
(stable, mild, or severe) over 2 years were analyzed. Cumulative incidence of clinical out-
come was determined by Kaplan-Meier analysis and Cox regression was used to evaluate
predictors of clinical outcome. In all, 470 patients with 60 events were used to develop
models to predict clinical decompensation. Baseline values of all four variables
were predictive of decompensation. There was a general trend of increasing outcomes
with more marked worsening of laboratory values over 2 years, particularly for patients
with abnormal baseline values. A model that included baseline platelet count, AST/ALT
ratio, bilirubin, and severe worsening of platelet count, bilirubin, and albumin was the
best predictor of clinical decompensation. A total of 483 patients with 79 events were
used to evaluate predictors of liver-related death or liver transplant. A model that included
baseline platelet count and albumin as well as severe worsening of AST/ALT ratio
and albumin was the best predictor of liver-related outcomes. Conclusion: Both the
baseline value and the rapidity in change of the value of routine laboratory variables
were shown to be important in predicting clinical outcomes in patients with advanced
chronic hepatitis C. (HEPATOLOGY 2011;54:1527-1537)
P
redicting clinical outcomes in patients with
chronic hepatitis C has been a challenge. Most
models to predict clinical and histological out-
comes have used baseline clinical or laboratory data.1-7
However, as the severity of liver disease changes over
time, so do the surrogate laboratory tests that reﬂect
the state of liver function. Therefore, a prognostic
model should take the time factor into account and a
laboratory parameter measured serially over time may
be more accurate in predicting outcome compared to a
single measurement obtained at baseline. In clinical
practice, physicians use serial clinical data and patterns
of laboratory values during follow-up to counsel
patients on their risks of adverse outcomes. Thus, a
patient with more rapidly deteriorating laboratory
values is expected to have a higher risk of an adverse
outcome than a patient with stable laboratory values
even though the baseline laboratory values of the two
Abbreviations: AFP, alpha fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CT, computed tomography; HALT-C, hepatitis C long-
term treatment against cirrhosis; HCC, hepatocellular carcinoma; HR, hazards ratio; INR, international normalized ratio; MELD, Model for Endstage Liver
Disease; MRI, magnetic resonance imaging.
From the 1Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and
Human Services, Bethesda, MD; 2New England Research Institutes, Watertown, MA; 3Ofﬁce of the Director, National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; 4Division of Digestive Diseases and Nutrition, and
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human
Services, Bethesda, MD; and 5Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI.
Received June 20, 2011; accepted June 27, 2011.
1527
patients may be similar. This approach of using serial
laboratory data to compute time-dependent Model for
Endstage Liver Disease (MELD) scores has been
shown to be more accurate in predicting wait list mor-
tality than listing MELD in patients waiting for liver
transplantation.8-10
The HALT-C (hepatitis C long-term treatment
against cirrhosis) trial enrolled 1,050 patients with
advanced hepatitis C followed prospectively to 8.7
years for clinical outcomes.11 All the patients had labo-
ratory tests at each study visit. The aim of this analysis
was to develop models comprising baseline values of
routinely available laboratory tests together with
changes in these values during follow-up to predict
outcomes in patients with advanced hepatitis C.
Patients and Methods
The design of the HALT-C trial has been
described.12 Brieﬂy, patients with chronic hepatitis C
had to meet the following criteria for enrollment: fail-
ure to achieve sustained virologic response after previ-
ous interferon treatment with or without ribavirin, the
presence of advanced ﬁbrosis on liver biopsy (Ishak ﬁ-
brosis score 3), no history of hepatic decompensation
or hepatocellular carcinoma (HCC), and the absence
of deﬁned exclusion criteria.
All patients were to receive the combination of full-
dose peginterferon and ribavirin during the lead-in
phase of the trial. Patients who remained viremic dur-
ing the lead-in phase of treatment (lead-in patients),
those who experienced virological breakthrough or
relapse after initial response (breakthrough/relapser
patients), and those who were nonresponders to pegin-
terferon and ribavirin outside of the HALT-C trial
(express patients) were randomized to maintenance
therapy (peginterferon alpha-2a 90 lg weekly) or to
remain as untreated controls for the next 3.5 years.
Following completion of the 3.5 years of the random-
ized trial, all patients were invited to continue follow-
up without treatment until October 20, 2009.
At entry, all patients were required to have an ultra-
sound, computed tomography (CT), or magnetic reso-
nance imaging (MRI) demonstrating no evidence of
hepatic mass lesions suspicious for HCC and to have
an alpha fetoprotein (AFP) <200 ng/mL. All patients
had a liver biopsy performed prior to enrollment. The
Ishak scoring system was used to grade inﬂammation
(0-18) and to stage ﬁbrosis (0-6).13 The patients were
seen every 3 months during the randomized phase of
the trial and every 6 months thereafter. At each visit,
patients were assessed clinically for outcomes and
blood was drawn for complete blood count, hepatic
panel (albumin, total bilirubin, aspartate aminotrans-
ferase [AST], alanine aminotransferase [ALT], and
alkaline phosphatase), creatinine, prothrombin time /
international normalized ratio (INR), and AFP. Upper
gastrointestinal endoscopy was performed at random-
ization to assess for esophageal varices. Ultrasound was
performed at randomization, 6 months after random-
ization, and then every 12 months during the random-
ized trial and every 6 months during the extended fol-
low-up period. Patients with an elevated or rising AFP
and those with new lesions on ultrasound were eval-
uated further with a CT or MRI. Diagnostic liver bi-
opsy and HCC treatment were conducted at the dis-
cretion of investigators at each site.
In this analysis, only patients randomized to no
treatment were included because interferon even in
low doses can have an effect on laboratory values. To
assess changes in laboratory values during follow-up,
only patients who had been followed up to month 24
from enrollment (18 months after randomization to
no treatment) with no outcomes up to that timepoint
were included. Two clinical outcomes were analyzed:
Outcome 1, Clinical decompensation, was deﬁned as
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any of the following: variceal bleeding, ascites, spontane-
ous bacterial peritonitis, and hepatic encephalopathy;
and Outcome 2, Liver-related deaths and liver transplan-
tation. Diagnostic criteria were established for each clini-
cal outcome and an Outcomes Review Panel adjudicated
each outcome report. Only the ﬁrst clinical outcome for
each patient was included in this analysis.
Statistical Analyses. Statistical analyses were
performed at the Data Coordinating Center with SAS
(v. 9.2).
Four laboratory parameters were chosen for evalua-
tion based on a prior multivariate analysis demonstrat-
ing their utility in predicting clinical and histological
outcome in the HALT-C trial,1 and whether they were
widely available. These included platelet count, serum
albumin, total bilirubin, and AST/ALT ratio. We
selected baseline cutoffs for the current analysis based
on a clinically meaningful value close to the median to
dichotomize the cohort into high- and low-risk groups.
These values were 150 k/mm3 for baseline platelets,
3.9 mg/dL for baseline albumin, 0.7 mg/dL for base-
line total bilirubin, and a ratio of 0.8 for baseline
AST/ALT ratio. Changes in laboratory values were
assessed by comparing values at the month 24 visit
(18 months after randomization to no treatment) and
baseline visit and categorized as stable (unchanged or
less than 5% worsening), mild worsening (5%-15%
change from baseline), and severe worsening (>15%
worsening from baseline). The selected values of percent
change from baseline used to deﬁne mild and severe
worsening in laboratory values were arbitrary because
there was no literature to reference regarding the chosen
categories. The speciﬁc ranges we chose were to enable
sufﬁcient numbers of patients in each of the three cate-
gories (stable, mild, and severe) to allow for meaningful
statistical analysis. The percent changes from baseline
was computed based on the following formula, %
change ¼ (follow-up value-baseline value)/Baseline
value*100. Patients with an outcome or censoring prior
to the month 24 visit were excluded from the analyses.
Cumulative incidence of clinical outcome was deter-
mined by Kaplan-Meier analysis and Cox regression
was used to evaluate predictors of clinical outcome.
Patients with both baseline and month 24 values in
platelet count, AST/ALT ratio, total bilirubin, and
albumin were used to develop the predictive models of
outcomes and patients with any missing values in
any of the four laboratory variables selected were
excluded to ensure the same sample size for each
outcome (N ¼ 470 for clinical decompensation and
N ¼ 483 for liver-related death/liver transplant) was
used in each model. The model ﬁt statistics (2 log
likelihood ratio, AIC and SBC) were used to compare
models for each outcome, with a lower value indicating a
more desirable model. The patients were stratiﬁed into
low, intermediate, and high risks for clinical decompensa-
tion based on risk scores of <75th percentile, 75th-90th
percentile, and >90th percentile, respectively.
Results
Of the 533 patients randomized to the control
group, 63 were excluded from the analyses of clinical
decompensation for the following reasons: 18 had an
outcome or censoring prior to month 24 and 45 had
missing month 24 laboratory values. The baseline
characteristics of the 470 patients included in this
analysis are listed in Table 1. The mean age of the
patients was 49.8 years, 71.3% were men, 70.2% were
white, 18.1% blacks, and 8.9% Hispanics. One hun-
dred ninety (40%) patients had cirrhosis (Ishak ﬁbrosis
score 5 or 6) and 25.5% had esophageal varices at the
time of randomization (month 6). During a median
follow-up of 6.3 years (range 1.4 to 8.7 years), 60
patients had clinical decompensation (variceal hemor-
rhage 1.5% [7/470], ascites 8.1% [38/470] and he-
patic encephalopathy 3.2% [15/470]) and 79 patients
experienced liver-related death or liver transplantation
(30 liver-related deaths, 44 liver transplantations, and
ﬁve deaths after liver transplantation). The indication
for liver transplantation was hepatic decompensation
in 26 and HCC with or without decompensation in
23 patients. The mean MELD score at the last study
visit obtained a mean of 6 months prior to transplan-
tation was 13 (range 6-23; 16 for those transplanted
for decompensation and nine for those transplanted
for HCC). Patients who developed clinical decompen-
sation were less likely to be white, had a higher body
mass index (BMI), lower albumin and platelet count,
and higher AST/ALT ratio, alkaline phosphatase, total
bilirubin, and INR at baseline compared to those
without clinical decompensation.
Clinical Decompensation
Platelet Count. Forty-ﬁve (21.5%) of 209 patients
with baseline platelet count 150 k/mm3 experienced
clinical decompensation compared to 15 (5.8%) of 261
with baseline platelet count >150 k/mm3 (Table 2).
Within each stratum of baseline platelet count, patients
who had severe worsening (>15% decrease between
month 24 and baseline) had a higher rate of clinical
decompensation than those with moderate (5% to 15%
decrease) or no to mild (<5% decrease) worsening.
The cumulative incidence of clinical decompensation at
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3, 5, and 7 years was 6.4%, 18.9%, and 26.8%, respec-
tively, for patients with baseline platelet 150 k/mm3
and 0.0%, 2.6%, and 7.4%, respectively, for those with
baseline platelet >150 k/mm3 (P < 0.0001) (Fig. 1A;
Supporting Table 2C). A sharp linear rise in decompen-
sation events was noted in those with baseline platelet
counts 150 k/mm3 after 24 months (18 months after
randomization to no treatment) of observation.
Among the patients with baseline platelet 150 k/
mm3, the cumulative incidence of clinical decompen-
sation at 3, 5, and 7 years was 5.2%, 13.3%, and
13.3%, respectively, for patients with stable platelet
count; 2.3%, 4.8%, and 18.5%, respectively, for those
with mild worsening of platelet count; and 11.0%,
36.3%, and 50.5%, respectively, for those with severe
worsening of platelet count (Fig. 1B; Supporting
Table 2C). For patients with baseline platelet >150 k/
mm3, the cumulative incidence of clinical decompensa-
tion at 3, 5, and 7 years was 0.0%, 1.7%, and 8.9%,
respectively, for patients with stable platelet count; 0.0%,
0.0%, and 0.0%, respectively, for those with mild
worsening of platelet count; and 0.0%, 7.0%, and
12.6%, respectively, for those with severe worsening of
platelet count (Fig. 1C; Supporting Table 2C).
Table 1. Characteristics of the Patients
Patients with Clinical
Decompensation (N 5 60)
Patients Without Clinical
Decompensation (N 5 410) Total Patients (N 5 470)
P-value
N or mean % or SD N or mean % or SD N or mean % or SD
Demographics
Age, years 49.7 6.90 49.8 7.09 49.8 7.06 0.87
Gender, male 42 70 293 71.5 335 71.3 0.82
Race
White 37 61.7 293 71.5 330 70.2 0.02
Black 12 20.0 73 17.8 85 18.1
Hispanic 11 18.3 31 7.6 42 8.94
Others 0 0.0 13 3.2 13 2.77
Metabolic factors
Diabetes 18 30 88 21.5 106 22.6 0.14
BMI, kg/m2 31.7 6.11 29.6 5.35 29.9 5.49 0.01
Lab values: baseline
Albumin (g/dL) 3.67 0.42 3.91 0.38 3.88 0.39 <0.0001
AST (U/L) 98.4 66.8 86.1 59.2 87.7 60.3 0.14
ALT (U/L) 104.3 69.5 112.5 84.8 111.4 83.0 0.48
AST/ALT ratio 1.02 0.31 0.84 0.28 0.86 0.29 <0.0001
Alk Phos (U/L) 120.1 53.5 95.3 46.5 98.5 48.1 0.0002
T Bilirubin (mg/dL) 1.00 0.52 0.74 0.35 0.77 0.39 <0.0001
INR 1.09 0.13 1.03 0.10 1.04 0.11 0.0002
Platelet (1,000/mm3) 128.9 57.9 172.6 66.7 167.0 67.2 <0.0001
Lab values: month 24
Albumin (g/dL) 3.36 0.53 3.83 0.42 3.77 0.46 <0.0001
AST (U/L) 100.7 51.5 82.7 57.1 85.0 56.7 0.02
ALT (U/L) 93.8 42.3 99.9 73.9 99.1 70.6 0.54
AST/ALT ratio 1.12 0.36 0.89 0.30 0.92 0.32 <0.0001
Alk Phos (U/L) 131.5 59.9 97.7 44.7 102.0 48.2 <0.0001
T Bilirubin (mg/dL) 1.38 0.87 0.90 0.49 0.96 0.57 <0.0001
INR 1.15 0.13 1.08 0.26 1.09 0.25 0.03
Platelet (1,000/mm3) 109.6 53.4 167.0 69.2 159.6 70.0 <0.0001
Change in lab value**: (Month 24-baseline)
Albumin (g/dL) 0.31 0.41 0.07 0.34 0.10 0.36 <0.0001
AST (U/L) 2.23 67.1 3.47 57.6 2.74 58.8 0.48
ALT (U/L) 10.5 55.9 12.6 79.6 12.3 77.0 0.84
AST/ALT ratio 0.10 0.25 0.06 0.20 0.06 0.21 0.12
Alk Phos (U/L) 11.5 39.2 2.37 28.1 3.53 29.8 0.03
T Bilirubin (mg/dL) 0.38 0.69 0.16 0.41 0.19 0.46 0.001
INR 0.07 0.12 0.05 0.25 0.05 0.24 0.59
Platelet (1,000/mm3) 19.4 32.1 5.58 32.2 7.33 32.5 0.002
Liver histology: Baseline
Ishak Fibrosis score 4.65 1.10 4.01 1.26 4.09 1.26 0.002
HAI 7.08 2.04 7.54 2.04 7.48 2.04 0.10
Steatosis score 1.38 0.78 1.31 0.88 1.32 0.87 0.53
Endoscopy: month 24
Esophageal varices 30 50 88 21.8 118 25.5 <0.0001
1530 GHANY ET AL. HEPATOLOGY, November 2011
AST/ALT Ratio. Forty-four (19%) of 232 patients
with baseline AST/ALT ratio >0.8 experienced clinical
decompensation compared to 16 (6.7%) of 238 with
baseline AST/ALT ratio 0.8 (Table 2). Within each
stratum of baseline AST/ALT ratio, patients who had
severe worsening (>15% increase between month
24 and baseline) had a higher rate of clinical decom-
pensation. The cumulative incidence of clinical decom-
pensation at 3, 5, and 7 years is shown in Supporting
Table 2C.
Total Bilirubin. Forty-eight (18.3%) of 263
patients with baseline total bilirubin >0.7 mg/dL
experienced clinical decompensation compared to 12
(5.8%) of 207 with baseline total bilirubin 0.7 mg/
dL (Table 2). Within each stratum of baseline total
bilirubin, patients who had severe worsening (>15%
increase between month 24 and baseline) had a higher
rate of clinical decompensation. The cumulative inci-
dence of clinical decompensation at 3, 5, and 7 years
is shown in Supporting Table 2C.
Albumin. Forty-three (16.5%) of 261 patients with
baseline albumin 3.9 mg/dL experienced clinical
decompensation compared to 17 (8.1%) of 209 with
baseline albumin >3.9 mg/dL (Table 2). Within each
stratum of baseline albumin, patients who had severe
worsening (>15% decrease between month 24 and
baseline) had a higher rate of clinical decompensation.
The cumulative incidence of clinical decompensation
at 3, 5, and 7 years is shown in Supporting Table 2C.
Multivariate Models to Predict Clinical Decom-
pensation. A multivariate model including baseline
platelet count, AST/ALT ratio, bilirubin, and albumin
(Model IA) showed that each of these four baseline
laboratory values independently predicted the
Table 2B. Prediction of Clinical Decompensation Based on Change in Laboratory Value from Baseline to Month 48
No. of Patients No. of Patients No. of Patients No. of Patients
Month 48-Baseline
(change)
Platelet x
1,000/mm3
No. (%) with
Outcome
AST/ALT
Ratio
No. (%) with
Outcome
T Bilirubin
(mg/dL)
No. (%) with
Outcome
Albumin
(g/dL)
No. (%) with
Outcome
Baseline 150 Baseline >0.8 Baseline >0.7 Baseline 3.9
Stable <5% 84 4 (4.8%) 98 7 (7.1%) 102 7 (6.9%) 151 6 (4.0%)
Worse, 5-15% 22 1 (4.5%) 27 1 (3.7%) 25 3 (12.0%) 45 5 (11.1%)
Worse, >15% 66 16 (24.2%) 69 14 (20.3%) 95 14 (14.7%) 27 10 (37.0%)
Total 172 21 (12.2%) 194 22 (11.3%) 222 24 (10.8%) 223 21 (9.4%)
Baseline >150 Baseline 0.8 Baseline .7 Baseline >3.9
Stable <5% 121 2 (1.6%) 64 0 (0.0%) 47 0 (0.0%) 107 4 (3.7%)
Worse, 5-15% 41 2 (4.9%) 43 3 (7.0%) 0 0 (0.0%) 65 5 (7.7%)
Worse, >15% 79 10 (12.7%) 112 10 (8.9%) 144 11 (7.6%) 18 5 (27.8%)
Total 241 14 (5.8%) 219 13 (5.9%) 191 11 (5.8%) 190 14 (7.4%)
Table 2A. Prediction of Clinical Decompensation Based on Change in Laboratory Value from Baseline to Month 24
No. of Patients No. of Patients No. of Patients No. of Patients
Month 24-Baseline
(Change)
Platelet 3
1,000/mm3
No. (%) with
Outcome AST/ALT Ratio
No. (%) with
Outcome
T Bilirubin
(mg/dL)
No. (%) with
Outcome
Albumin
(G/Dl)
No. (%) with
Outcome
Baseline 150 Baseline >0.8 Baseline >0.7 Baseline 3.9
Stable <5% 99 12 (12.1) 129 23 (17.8) 124 14 (11.3) 161 15 (9.3)
Worse, 5-15% 43 5 (11.6) 44 6 (13.6) 35 6 (17.1) 81 19 (23.5)
Worse, >15% 67 28 (41.8) 59 15 (25.4) 104 28 (26.9) 19 9 (47.4)
Total 209 45 (21.5) 232 44 (19) 263 48 (18.3) 261 43 (16.5)
Baseline >150 Baseline 0.8 Baseline .7 Baseline >3.9
Stable <5% 131 7 (5.3) 94 4 (4.3) 53 0 115 8 (7)
Worse, 5-15% 66 1 (1.5) 41 6 (14.6) 0 0 85 5 (5.9)
Worse, >15% 64 7 (10.9) 103 6 (5.8) 154 12 (7.8) 9 4 (44.4)
Total 261 15 (5.8) 238 16 (6.7) 207 12 (5.8) 209 17 (8.1)
P-value to compare % categories among the group with PLT 150:P < 0.0001.
P-value to compare % categories among the group with PLT> 150:P ¼ 0.0749.
P-value to compare % categories among the group with AST/ALT 0.8:P ¼ 0.0766.
P-value to compare % categories among the group with AST/ALT> 0.8:P ¼ 0.2833.
P-value to compare % categories among the group with Bili 0.7:P ¼ 0.0392.
P-value to compare % categories among the group with Bili> 0.7:P ¼ 0.0096.
P-value to compare % categories among the group with Albumin 3.9:P< 0.0001.
P-value to compare % categories among the group with Albumin> 3.9:P¼ 0.0002.
Fisher’s Exact Test.
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occurrence of clinical decompensation (Table 3A). A
model including changes in values of these four labora-
tory tests between month 24 and baseline (Model IIA)
found that severe worsening (>15% change) but not
mild worsening (5%-15% change) of platelet count,
bilirubin, as well as albumin were independent predic-
tors of clinical decompensation, whereas changes in
AST/ALT ratio were not. Inclusion of both baseline
laboratory values and changes in laboratory values
(Model IIIA) showed that baseline platelet, AST/ALT
ratio, and bilirubin; and severe worsening of platelet
count, bilirubin, and albumin were independent pre-
dictors of clinical decompensation. Model IIIA has the
lowest AIC (621), indicating that it has a better ﬁt
than Model IA (AIC: 651) and Model IIA (AIC:
655). Addition of age, gender, and race did not
improve the ﬁt of any of these models. The duration
of follow-up was similar among the three categories of
change for each variable irrespective of whether the
variable was normal or abnormal at baseline and did
not impact the accuracy of the model.
To address the issue whether a longer observation
period would have any effect on the accuracy of the
model, we used change in laboratory values from base-
line to month 48 (Table 2B), and compared the results
with those obtained using change in laboratory values
from baseline to month 24. For patients whose base-
line laboratory values were abnormal, extending the
observation period from 24 to 48 months resulted in
lower outcome rate, i.e., slower worsening of labora-
tory values was associated with a lower rate of adverse
outcome. During the period between month 24 and
48, 25/60 (42%) patients with abnormal baseline labo-
ratory values experienced a decompensation outcome.
In contrast, for patients whose baseline labs were nor-
mal the outcome rate for each category of change
from baseline to M48 was similar to same category of
change from baseline to M24.
The cumulative incidence of clinical decompensation
in the low-, intermediate-, and high-risk groups based
on Model IA and Model IIIA are shown in Fig. 2.
Table 4 illustrates the application of these models to
four examples of patients. Patients A and B (baseline
platelet count >150 k/mm3, AST/ALT ratio <0.8, total
bilirubin <0.7 mg/dL, and albumin >3.9 mg/dL) fell
into the low-risk category based on both Models IA
and IIIA, whereas patient C (baseline platelet count
<150 k/mm3, AST/ALT ratio >0.8, total bilirubin
>0.7 mg/dL, and albumin <3.9 mg/dL) with stable/
mild change in laboratory values was classiﬁed as inter-
mediate risk by Model IA and low risk by Model IIIA
and patient D (baseline platelet count <150 k/mm3,
AST/ALT ratio >0.8, total bilirubin >0.7 mg/dL, and
albumin <3.9 mg/dL) with mild/severe change in
laboratory values was classiﬁed as intermediate risk by
Model IA and high risk by Model IIIA.
Liver-Related Death or Liver Transplant
Bivariate Cox regression analyses of baseline labora-
tory values found that all four baseline laboratory val-
ues predicted liver-related death or liver transplant:
platelet 150 k/mm3 (hazards ratio [HR] 5.48, 95%
conﬁdence interval [CI] 3.17-9.5), AST/ALT ratio
<0.8 (HR 0.36, 95% CI 0.22-0.58), bilirubin
<0.7 mg/dL (HR 0.51, 95% CI 0.31-0.82), and albu-
min <3.9 g/dL (HR 3.4, 95% CI 2.0-5.81). When
Fig. 1.
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Table 3B. Multivariate Cox Models to Predict Liver-Related Deaths or Liver Transplants
Model IB Model IIB Model IIIB
HR 95% CI HR 95% CI HR 95% CI
Baseline lab values
Platelet count  150 vs. > 150 4.110 2.307-7.321 4.143 2.296-7.476
AST/ALT ratio  0.8 vs. > 0.8 0.558 0.342-0.910 0.657 0.396-1.091
T Bilirubin  0.7 vs. > 0.7 0.890 0.543-1.459 0.940 0.544-1.625
Albumin 3.9 vs. >3.9 2.357 1.363-4.076 2.329 1.334-4.064
Change in lab values, month 24 -baseline
Platelet count
5-15% worse vs. stable 0.922 0.474-1.793 0.940 0.479-1.844
>15% worse vs. stable 1.812 1.077-3.046 1.662 0.986-2.803
AST/ALT ratio
5-15% worse vs. stable 1.707 0.950-3.070 2.146 1.162-3.964
>15% worse vs. stable 0.964 0.573-1.621 1.300 0.757-2.232
T Bilirubin
5-15% worse vs. stable 1.107 0.428-2.865 1.065 0.415-2.732
>15% worse vs. stable 1.695 1.014-2.833 1.570 0.916-2.691
Albumin
5-15% worse vs. stable 1.470 0.879-2.458 1.318 0.778-2.234
>15% worse vs. stable 5.724 3.021-10.85 3.569 1.825-6.979
Model ﬁt statistics
-2 LOG L 845.113 863.141 809.034
AIC 853.113 879.141 833.034
SBC 862.591 898.097 861.467
No. of patients ¼ 483, no. of events ¼ 79.
Model IB compared to Model IIIB P< 0.0001 by Likelihood ratio test.
Model IIB compared to Model IIIB P < 0.0001 by Likelihood ratio test.
Formulae are provided as Supporting material to Table 3B and on the HALT-C website at http://www.haltctrial.org.
Table 3A. Multivariate Cox Models to Predict Clinical Decompensation
Model IA Model IIA Model IIIA
HR 95% CI HR 95% CI HR 95% CI
Baseline lab values
Platelet (x1,000/mm3)  150 vs. > 150 2.893 1.568-5.338 2.766 1.472-5.199
AST/ALT ratio  0.8 vs. > 0.8 0.416 0.233-0.743 0.500 0.270-0.925
T Bilirubin (mg/dL)  0.7 vs. > 0.7 0.404 0.211-0.775 0.375 0.185-0.759
Albumin (g/dL)  3.9 vs. >3.9 1.801 1.014-3.200 1.508 0.822-2.767
Change in lab values, month 24 - baseline
Platelet count
5-15% worse vs. stable 0.631 0.249-1.598 0.560 0.219-1.436
>15% worse vs. stable 2.717 1.502-4.914 2.292 1.268-4.145
AST/ALT ratio
5-15% worse vs. stable 1.268 0.625-2.572 1.503 0.726-3.113
>15% worse vs. stable 0.892 0.498-1.597 1.278 0.690-2.367
T Bilirubin
5-15% worse vs. stable 2.135 0.786-5.797 1.963 0.732-5.268
>15% worse vs. stable 2.083 1.116-3.888 2.626 1.376-5.009
Albumin
5-15% worse vs. stable 1.585 0.877-2.865 1.361 0.740-2.506
>15% worse vs. stable 6.466 3.120-13.40 3.854 1.816-8.180
Model ﬁt statistics
-2 LOG L 642.789 639.433 596.792
AIC 650.789 655.433 620.792
SBC 659.166 672.188 645.924
No. of patients ¼ 470, no. of events ¼ 60.
Model IA compared to Model IIIA P< 0.0001 by Likelihood ratio test.
Model IIA compared to Model IIIA P< 0.0001 by Likelihood ratio test.
Formulae are provided as Supporting material to Table 3A and on the HALT-C website at http://www.haltctrial.org.
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changes in laboratory values between month 24 and
baseline were analyzed, severe worsening (>15%
change) of all laboratory values was predictive of liver-
related death or liver transplant.
A multivariate model including baseline platelet
count, AST/ALT ratio, bilirubin, and albumin (Model
IB) showed that baseline platelet, AST/ALT ratio, and
albumin were predictive of liver-related death or liver
transplant (Table 3B). A model including changes in
values of these four laboratory tests (Model IIB)
between month 24 and baseline found that severe wor-
sening of platelet count, total bilirubin, and albumin
were predictive of liver-related death or liver trans-
plant. Inclusion of both baseline laboratory values and
changes in laboratory values (Model IIIB) showed that
baseline platelet count and albumin as well as moder-
ate worsening of AST/ALT ratio and severe worsening
of albumin were predictive of liver-related death or
liver transplant. Model IIIB had the lowest AIC (833),
indicating that it has a better ﬁt than Model IB (AIC:
853) and Model IIB (AIC: 879).
Validation of Models
We utilized all patients randomized to the low-dose
peginterferon arm of the HALT-C trial as a validation
cohort for the two models. We also assessed perform-
ance of the model in patients with cirrhosis using
control and treated patients with cirrhosis. For both
models (model for prediction of clinical decompensa-
tion and model for liver deaths or transplants) the
analysis revealed no statistical difference in outcomes
between control and treated patients in any of the
three risk categories (low, intermediate, or high) (Sup-
porting Fig. 1a-d). Comparison of the models between
control and treated patients with cirrhosis yielded simi-
lar results (data not shown).
Discussion
The HALT-C trial enrolled more than 1,000
patients with advanced hepatitis C who were prospec-
tively followed for up to 8.7 years for clinical out-
comes. Half of the subjects served as control patients,
which provided the opportunity to deﬁne the natural
history of advanced chronic hepatitis C. We had previ-
ously identiﬁed four clinical variables, platelet count,
AST/ALT ratio, total bilirubin, and albumin, to be
predictive of clinical and histological progression in
patients with chronic hepatitis C.1 The current analysis
focused on whether including the change (stable or
worse) from baseline in each of these laboratory values
over a 24-month period would be superior to the base-
line value in predicting two clinically relevant out-
comes in previously treated patients with chronic hepa-
titis C: clinical decompensation (including ascites,
spontaneous bacterial peritonitis, variceal hemorrhage,
and hepatic encephalopathy) and liver-related death
and liver transplant. The analysis demonstrated that
the outcome of advanced chronic hepatitis C was de-
pendent not only on the value of the laboratory pa-
rameter at initial presentation, but also on the magni-
tude of the change in the particular parameter over
time. The two models that incorporated both baseline
and change in laboratory values over a 24-month pe-
riod (Models IIIA and IIIB) were the most accurate in
predicting clinical outcome in patients with advanced
chronic hepatitis C.
Approximately 17%-22% of patients with baseline
laboratory values below the cutoff developed a decom-
pensation event compared to only 6%-8% of those
above the cutoff. Categorizing the change from
Table 4. Application of Models 1A and IIIA to Predict Risks of Clinical Decompensation
Patient
Platelet Count AST/ALT ratio Total Bilirubin Albumin Risk Scores
Baseline M24 Baseline M24 Baseline M24 Baseline M24 Model IA Model IIA Model IIIA
A 200 190 0.7 0.8 0.4 0.4 4.3 4.3 1.78 low 0.22 low 1.85 low
B 200 160 0.7 0.8 0.4 0.4 4.3 4 1.78 low 1.70 inter 0.13 low
C 110 100 0.9 1 0.75 0.75 3.7 3.6 1.65 inter 0.22 low 1.26 low
D 110 80 0.9 1.2 0.75 0.8 3.7 3.4 1.65 inter 2.10 high 3.49 High
Fig. 2.
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baseline in the laboratory parameter into three grades
of worsening (stable to mild, moderate, and severe)
over a 24-month period allowed a better risk stratiﬁca-
tion for development of a clinical outcome than the
baseline value alone over an 8-year period. There was
a linear increase in clinical decompensation with wor-
sening laboratory values, with the exception of AST/
ALT ratio, and the rate of events was signiﬁcantly
higher in those with a >15% worsening in laboratory
values compared to those with a stable laboratory
value. Thus, 12% of patients with a baseline platelet
count 150 k/mm3 who had a <5% change over
24 months developed a clinical outcome compared to
42% of those who had a >15% change over the same
time period. The rate of clinical outcomes was also de-
pendent on the baseline laboratory value. Only 6% of
patients with a baseline platelet count >150 k/mm3
and a >15% worsening in platelet count over
24 months developed a clinical outcome compared to
42% of those with a baseline platelet count of
150 k/mm3 and similar degree of worsening over
24 months. Thus, monitoring the rate of change of
laboratory values should allow physicians to better pre-
dict the risk of a patient developing a clinical outcome.
Ideally, it would be preferable if models could be devel-
oped to accurately predict the risk of a clinical outcome
at the time of initial evaluation or after a short period of
observation. However, this will be difﬁcult if not impos-
sible because every patient is at a different point in the
natural history at the time of presentation and has dif-
ferent rates of disease progression. In general, changes in
laboratory values over time periods of less than a year
reﬂect changes around the mean and are not consistently
accurate enough to be used for prediction purposes
unless a deﬁnite trend is observed. We calculated the
slope of the rate of change of the laboratory parameters
over 12, 24, and 48 months and found it difﬁcult to
interpret because of ﬂuctuations in the laboratory values
at each visit. However, we found that the rapidity of
change in the laboratory value was important as a pre-
dictor of a clinical outcome.
Extending the observation period from 48 months
instead of 24 months from baseline was associated
with an almost 50% lower rate of outcomes in each of
the risk categories among those with abnormal baseline
laboratory values. This is because a substantial propor-
tion of patients with more rapid progression of disease
(42%) developed an outcome between month 24 and
48. In contrast, among patients with normal baseline
laboratory values there was no signiﬁcant difference in
the rate of outcomes for the same category of change
in laboratory values after a 24- or 48-month interval.
This may be related to the low rate of outcome in
patients with normal baseline laboratory values In
addition, laboratory values may remain within the nor-
mal range in some of these patients despite a change
from baseline. For patients with normal baseline labo-
ratory values, additional studies are needed to develop
models based on longer periods of observation.
We conﬁrmed the accuracy of our two models using
the patients randomized to treatment as a validation
cohort. Both models (model for prediction of clinical
decompensation and model for liver deaths or trans-
plants) performed well and there was no statistical dif-
ference in outcomes between control and treated
patients in any of the three risk categories (low, inter-
mediate, or high). The models also performed equally
well in the subset of patients with cirrhosis. Thus, we
believe these models can be helpful, allowing more
accurate risk stratiﬁcation than reliance on baseline
laboratory values only in determining frequency of
monitoring and screening procedures.
The multivariate Cox model using a time-dependent
covariate identiﬁed change from baseline in platelet
count, total bilirubin, and albumin but not AST/ALT
ratio as independent predictors of a clinical decompensa-
tion event. This probably relates to the fact that
clinical decompensation is related to the severity of
portal hypertension and synthetic dysfunction. Individ-
ual ALT and AST values correlate better with underlying
necroinﬂammation and have been shown to be predictive
of ﬁbrosis progression.7,14 The AST/ALT ratio has been
shown to be a predictor of cirrhosis15 but not of hepatic
synthetic dysfunction.11 It is possible that if changes in
AST and ALToccur in the same direction, it would have
a minimal effect on the AST/ALT ratio. Thus, monitor-
ing the AST/ALT ratio was not found to be helpful in
predicting a clinical decompensation outcome.
Fig. 3.
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A model including baseline platelet count and albu-
min together with worsening serum albumin and AST/
ALT ratio (Model IIIB) was the best predictor of liver-
related death or liver transplant. Interestingly, neither
baseline serum bilirubin nor change in bilirubin level
over 24 months was predictive of liver-related death or
liver transplant. This may be related to the fact that a
substantial number of deaths and liver transplants in
this analysis were due to HCC and not decompensation.
Removal of HCC as an outcome resulted in bilirubin
being a signiﬁcant predictor of liver-related outcomes.
Many models have been developed to predict sever-
ity of ﬁbrosis and cirrhosis in patients with chronic
hepatitis C. Only a few have looked at clinical out-
comes but these models have used laboratory tests that
are not widely available or the sample size has been
small with limited follow-up.16 The strength of this
study was the large number of patients who were pro-
spectively monitored for over 8 years for liver out-
comes and each outcome was adjudicated by a review
panel. The combined model using baseline laboratory
values in combination with a change in the laboratory
value over a 24-month period was the most accurate at
predicting risk of a clinical outcome.
We chose not to consider the most recent laboratory
values when determining whether a change in laboratory
values was important. This analytic approach would ne-
cessitate selecting an arbitrary timepoint as ‘‘current.’’
Moreover, the approach we selected more closely resem-
bles that used in clinical practice, beginning with a base-
line laboratory value and monitoring the change pro-
spectively. We selected a 24-month period for
calculating change in laboratory values from baseline.
This was a compromise over an earlier timepoint which
would not allow sufﬁcient time for the laboratory values
to change (or only detect patients with rapid changes)
and a later time period such as 48 months, which meant
patients with early outcomes, would be excluded. We
believe using changes in laboratory values over a shorter
time period (<24 months) in our model would underes-
timate the risk of a clinical outcome. We showed that
calculating the risk score using changes in laboratory val-
ues over a longer period (48 months) would overesti-
mate the risk because the latter patient would in reality
have a slower rate of worsening in laboratory values than
our model would suggest. Our models were derived
from patients followed for a median of 6.3 and maxi-
mum of 8.7 years; these models may not apply to lon-
ger-term predictions. We did not assess whether the
model could be utilized for repeat measurements over
time, always maintaining a 2-year interval between labo-
ratory assessments.
A reasonable criticism of our approach is that one
has to wait a minimum of 24 months before the
model could be used. In the HALT-C cohort, only
3.8% of patients had a clinical outcome during this
period. Moreover, even in patients with cirrhosis, 80%
are alive at 10 years, which would allow sufﬁcient time
to intervene if the model suggested a higher rate of
outcomes.17 Finally, the model could be used on retro-
spective data on any patient in whom 2 years of fol-
low-up is available. Thus, our models can be applied
to patients who have historical laboratory values up to
2 years prior to presentation. For patients with no his-
torical laboratory values, the models that include base-
line laboratory values only can be used to predict out-
comes at the time of presentation and the prediction
reﬁned after the patient had been followed for 2 years.
All of the patients used in this analysis had previously
failed therapy and it is unclear how the model would
perform on an untreated cohort. Therefore, it would
be important to validate the model in other popula-
tions with advanced chronic hepatitis C.
In conclusion, we developed two straightforward
models using widely available laboratory tests to accu-
rately predict the outcome of advanced chronic hepati-
tis C. We demonstrated that the change in an individ-
ual laboratory variable over time complements the
baseline value of that variable as a predictor of a clini-
cal decompensation in patients with advanced chronic
hepatitis C. Furthermore, the rapidity of the change is
associated with the development of outcomes. Such in-
formation may be useful to the physician for designing
a monitoring schedule and timely referral for liver
transplantation, to patients in planning for the future,
and to third-party payers for allocation of resources for
screening and monitoring.
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